---
title: "Quanterix Corp 2026: Revenue $32.91M, EPS ($1.04) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295409153.md"
description: "Quanterix Corp reported Q2 2026 results with revenue of $32.91M, up 34.4% YoY, driven by the Akoya acquisition. Despite a net loss of ($48.93M) and diluted EPS of ($1.04), the company achieved $85M in annualized cost synergies from integration. Key progress includes CMS reimbursement for LucentAD Complete, a submitted 510(k) for an Alzheimer’s test, and plans for FDA IVD approval by 2027."
datetime: "2026-08-10T12:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295409153.md)
  - [en](https://longbridge.com/en/news/295409153.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295409153.md)
generator: "portal-rs"
---

# Quanterix Corp 2026: Revenue $32.91M, EPS ($1.04) — 10-Q Summary

Quanterix Corp reported results for the quarter ended 2026, with revenue of $32.91M, a net loss of ($48.93M) and diluted loss per share of ($1.04), versus $24.48M, ($30.01M) and ($0.77) in the year-ago quarter, respectively.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$32.91M

$24.48M

34.4%

Net income²

($48.93M)

($30.01M)

(63%)

Diluted EPS³

($1.04)

($0.77)

(35.1%)

*¹ Reported as “Total revenues”. ² Reported as “Net loss”. ³ Reported as “loss per common share, basic and diluted”.*

**Business Highlights**

-   Revenue growth was driven by the acquisition of Akoya, helping total revenue rise 26% year-to-date to $69.3M despite softness in legacy Quanterix products.
-   Akoya acquisition shifted the company’s channel and product mix, adding significant product and service revenue and increasing recurring consumables sales.
-   Regulatory and commercial progress included a submitted 510(k) for an Alzheimer’s multi‑analyte blood test and LucentAD Complete receiving CMS reimbursement with payer coverage beginning.
-   Operationally, the company completed Akoya integration, realizing approximately $85M of annualized cost synergies and consolidated systems; commercial leadership was reorganized and investments planned for sales, marketing and HD‑X upgrades to pursue FDA IVD approval in 2027.

Original SEC Filing: Quanterix Corp \[ QTRX \] - 10-Q - Aug. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [QTRX.US](https://longbridge.com/en/quote/QTRX.US.md)
- [AKYA.US](https://longbridge.com/en/quote/AKYA.US.md)

## Related News & Research

- [Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test](https://longbridge.com/en/news/296029225.md)
- [QTRX: Revenue up 34% year-over-year, but 2026 outlook lowered amid market softness and execution challenges](https://longbridge.com/en/news/295406519.md)
- [LyondellBasell announces dividend of R$ 1.72 per unit for 3Q 2026](https://longbridge.com/en/news/297814383.md)
- [Builders FirstSource to host 2026 investor day webcast](https://longbridge.com/en/news/297954126.md)
- [Target files 10-Q for quarter ended Aug. 1, 2026](https://longbridge.com/en/news/297788125.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**